Business
Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences
BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and
About this update from Ocular Therapeutix, Inc.
[{"type":"text","content":" BEDFORD, Mass.--(BUSINESS WIRE)--\nOcular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will participate at the following conferences:\n\nJefferies London Healthcare Conference\nFireside Chat Date: Wednesday November 16, 2022\nFireside Chat Time: 2:05 PM GMT\nLocation: Waldorf Hilton, London, UK\n\nBTIG Virtual Ophthalmology Day 2022\nFireside Chat Date: Tuesday, November 29, 2022\nFireside Chat Time: 8:30 AM EST\n\nPiper Sandler 34th Annual Healthcare Conference\nFireside Chat Date: Wednesday November 30, 2022\nFireside Chat Time: 12:00 PM EST\nLocation: Lotte New York Palace, New York, NY\n\nManagement will be available throughout the day for investor meetings at all three conferences. If you plan to attend at least one of the conferences and are interested in meeting with management, please contact your Jefferies, BTIG or Piper Sandler representative.\n\nA live webcast of the fireside chats at the Jefferies London Healthcare Conference and Piper Sandler 34th Annual Healthcare Conference can be accessed by visiting the Investors section of the Company’s website at investors.ocutx.com. It will also be available for replay for 90 days.\n\nAbout Ocular Therapeutix, Inc.\n\nOcular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix’s first commercial drug product, DEXTENZA®, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. Ocular Therapeutix’s earlier stage development assets include: OTX-TKI (axitinib intravitreal implant), currently in Phase 1 clinical trials for the treatment of wet AMD and other retinal diseases; OTX-TIC (travoprost intracameral implant), currently in a Phase 2 clinical trial for the treatment of primary open-angle glaucoma or ocular hypertension; and OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term ...